Use and Costs of Breast Cancer Screening for Women in Their 40s in a US Population With Private Insurance | Breast Cancer | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Research Letter
    March 23, 2020

    Use and Costs of Breast Cancer Screening for Women in Their 40s in a US Population With Private Insurance

    Author Affiliations
    • 1Department of Health Management and Health Economics, Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway
    • 2Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut
    • 3Department of Epidemiology and Biostatistics, Amsterdam UMC, Amsterdam, the Netherlands
    • 4Link Medical Research, Oslo, Norway
    • 5Section of General Internal Medicine, Yale School of Medicine, New Haven, Connecticut
    • 6Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut
    • 7Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut
    • 8Department of Population Health, New York University School of Medicine, New York
    JAMA Intern Med. 2020;180(5):799-801. doi:10.1001/jamainternmed.2020.0262

    Although professional society guidelines vary, most private insurance companies in the US will reimburse for the costs of mammography for women age 40 through 49 years.1 While the clinical benefits and harms of screening women in their 40s have been widely discussed,2,3 there is limited evidence regarding the cost implications of contemporary breast cancer–screening practices among this population. We estimated annual breast cancer screening–associated costs among US women in their 40s who have private insurance. We also assessed regional variation in these costs.

    We conducted a retrospective study of women aged 40 through 49 years who had private insurance using data from the Blue Cross Blue Shield Axis, a large commercial claims database accessed via a secure portal. We selected women between ages 40 and 49 years who were eligible to receive a screening mammography in 2017 and identified screening mammography in 2017 using a validated algorithm and relevant Current Procedural Terminology codes.4 For each beneficiary screened, we identified subsequent evaluation tests in the 4 months after the initial screening mammography and calculated the total annual cost of screening based on use and unit costs of initial screening (2-dimensional mammography with or without digital breast tomosynthesis [DBT]), supplementary screening (screening ultrasonography), recall (diagnostic 2-dimensional mammography with or without DBT and ultrasonography), and other diagnostic tests (magnetic resonance imaging and biopsy). We then estimated the mean cost per beneficiary screened.

    ×